Q-omics provides the consensus-scored METTL8 profile across patient tissues and cancer cell-line models. METTL8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, METTL8 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, METTL8 RNA expression shows 21,431 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where METTL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL8 survival associations across molecular data types. METTL8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL8 RNA expression–survival associations across cancer types. High METTL8 expression shows unfavorable associations in ACC, UCEC, LIHC, KIRP and UVM, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for METTL8 RNA expression.
This table summarizes METTL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for METTL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL8 shows lower tumor expression in THCA and higher tumor expression in HNSC, LUAD, LUSC, KIRP and CHOL. The HNSC box plot shows higher METTL8 RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with METTL8 in patient tissues and cancer cell lines. In patient samples, METTL8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
